Risvodetinib reduces key Parkinson's biomarkers in 12 week trial

Biotechnology company ABLi Therapeutics has completed an extensive biomarker study showing that its experimental drug risvodetinib can substantially reverse key biological processes involved in Parkinson's. The analysis involved 7,300 individual measurements taken from up to 80 participants in a 12 week clinical study known as the 201 Trial. Researchers examined samples of tissue, blood, and spinal fluid to measure how the drug affects biological changes taking place in the body. The findings focused on 11 key biological markers that track nerve degradation, cell energy production, and inflammation. ABLi Therapeutics measured these markers at the start of the study and again after 12 weeks of treatment. The results demonstrated that risvodetinib successfully blocked the activity of an enzyme called c Abl kinase, which is known to drive the progression of the condition. A major outcome of the study was a significant reduction in toxic protein clumps called phosphorylated alpha synuclein. Participants who received daily doses of 100 mg or 200 mg showed marked reductions of this protein in their spinal fluid, while all tested doses of 50 mg, 100 mg, and 200 mg produced reductions in blood samples. Earlier findings from the same trial had already shown that daily risvodetinib reduced these toxic protein deposits in skin biopsy samples from 36 participants. The study also demonstrated that risvodetinib lowered neuroinflammation across all three tested doses. Levels of inflammatory proteins, including NLRP3, interleukin 1 beta, and interleukin 18, dropped below their original baseline levels after 12 weeks. This indicates that the drug helped to quieten harmful immune reactions in both the central nervous system and the wider body. Risvodetinib is designed as a once daily oral therapy that aims to modify the underlying biology of Parkinson's rather than simply managing its symptoms. In an earlier placebo controlled clinical trial, it became the first single treatment to show an improvement in quality of life alongside a reduction in underlying protein buildup. ABLi Therapeutics plans to present these results to the United States Food and Drug Administration in August 2026 and will use the data to guide upcoming late stage clinical trials named BASE, ABILITY, and CAMPD.